CARDIOPROGRESS
Foundation for the advancement of cardiology

PARTNER 2A Intermediate-Risk TAVR Five-Year Results Hit Print Late outcomes of transcatheter aortic valve replacement (TAVR) in the PARTNER 2A trial are now enshrined in the peer-reviewed literature.

New report reveals the role of physical activity in preventing and treating cardiovascular diseases The European Heart Network, in collaboration with the WHO European Office for the Prevention and Control of Noncommunicable Diseases, has published an important report on physical activity policies for cardiovascular health. Each year, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. Physical inactivity increases the risk of cardiovascular diseases by more than 20%.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

Ticagrelor Sans Aspirin Trial Answers Some Questions About DAPT Hi. My name is Robert Byrne. I'm an interventional cardiologist at the German Heart Center in Munich and am here at TCT 2019 in San Francisco, where we've seen some interesting results from the TWILIGHT study. I would like to discuss some of the implications of this study for clinical practice.

From Naysayer to Convert: Cardiologists Should Prescribe SGLT2 Inhibitors Сardiologists have largely resisted calls to get more involved in diabetes. The comments on the Medscape article "Cardiologists Must Get Up to Speed on Treating Diabetes" echoed the sentiments of many regarding sodium-glucose contransporter-2 (SGLT2) prescribing.

MITRA-FR at 2 Years: MitraClip Still No Better Than Med Therapy Patrice Wendling PARIS — An additional year of follow-up in the MITRA-FR trial confirm no added benefit of percutaneous repair of functional mitral regurgitation (MR) with the MitraClip (Abbott) compared with optimal medical therapy alone.

Daily Aspirin May Lower Risk for Fatty Liver Progression Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in Clinical Gastroenterology and Hepatology.

Novel Carotid Filter Aims for Stroke Prevention in Afib Stroke prophylaxis with a novel permanent filter implanted in the carotid arteries is feasible for high risk atrial fibrillation (Afib) patients, a pilot trial showed.

Excess Vitamin D Linked to Kidney Damage Vitamin D has been reported to have a wide range of benefits. However, a recent case study indicates that excessive use of vitamin D can cause kidney damage in people who are not deficient in the vitamin.

Dad's Smoking Tied to Baby's Heart Defect Risk Results from a large meta-analysis indicate that paternal smoking during a mother's pregnancy is a significant and independent risk factor for congenital heart defects (CHD) among offspring, as is secondhand smoke exposure in general. Meta-analysis suggests smoke exposure from any source is problematic during pregnancy.

New State Law Will Restrict AI in Prior Authorization, Coverage Decisions California is taking aim at algorithms used by insurers to make prior authorization and other coverage decisions with a new law that will put limitations on how artificial intelligence (AI)–generated formulas are employed.

Development and validation of a machine learning model to predict myocardial blood flow and clinical outcomes from patients’ electrocardiograms Scientists have developed a machine learning (ML) model using electrocardiography (ECG) to predict myocardial blood flow reserve (MFR) and assess its predictive value in relation to major adverse cardiovascular events (MACEs). Using 3639 ECG positron emission tomography (PET) and 17,649 pairs of ECG single-photon emission computed tomography data (SPECT), the model is trained using the intelligent swarm intelligence approach and support vector regression (SVR).

e-Cigarettes Linked to Increased Stroke, MI Risk Use of electronic cigarettes (e-cigarettes) is linked to a significantly increased risk for "hard" adverse outcomes, such as stroke and myocardial infarction (MI), new research suggests. Among more than 400,000 respondents older than 18 years from the 2016 Behavioral Risk Factor Surveillance System (BRFSS) survey, almost 66,800 reported having ever used e-cigarettes.

INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS

Personal income may increase risk of heart disease Income levels, if they are unstable, can easily turn into a stressor. However, the volatility of personal income could be having a more serious effect on people's heart health. It is often expected that a person's income will constantly rise until they reach retirement age.

Weight-Adjusted Aspirin Dosing: Evidence Builds in Primary Prevention Low-dose aspirin intended for primary prevention, typically 75 to 100 mg once daily, doesn"t protect against cardiovascular events in persons who weigh at least 70 kg (about 154 pounds), suggests a patient-level analysis of randomized trials that included more than 100,000 patients. But daily aspirin at higher dosages, usually at least 300 mg, was cardioprotective in that group, as was low-dose aspirin in people who weighed less than 70 kg.

New ADA/EASD Guidance on Diabetes: Assess CV Status First The treatment approach to type 2 diabetes should begin with an assessment of cardiovascular disease (CVD) status, other comorbidities, and patient preferences, according to a draft of the upcoming 2018 joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). The final version of the 2018 update to the current 2015 ADA/EASDManagement of Hyperglycemia in Type 2 Diabetes statement (Diabetes Care.2015;38:140-149) will be presented on October 5, 2018 at the EASD annual meeting in Berlin and will be published in Diabetes Care and Diabetologia.

The Asian and the Commonwealth of Independent States Congress of Cardiologists and Therapeutics

Expert opinion. Double antiplatelet therapy after ACS: "de-escalation" In medical practice, cases in which patients with acute coronary syndrome (ACS) and received a combination of acetylsalicylic acid (ASA) with prasugrel or ticagrelor are often used, a combination of ASA with clopidogrel is started. This transition from more active platelet-derived P2Y12 blockers to less active clopidogrel has been termed "de-escalation." The possibility of "de-escalation" is considered in documents prepared by various expert groups. Among them, an updated version of the recommendations of the European Society of Cardiology and the European Association of Cardio Thoracic Surgeons for double antiplatelet therapy for coronary heart disease, where a similar transition is proposed to be discussed with side effects or intolerance of prasugrel / ticagrelor. There is also an agreement of experts from Europe and the USA, in which practical approaches to the replacement of the P2Y12 blocker of the platelet receptor are analyzed in detail. However, it should be borne in mind that these proposals are basically based on common sense and representations of the pharmacological properties of various P2Y12 receptor blockers of the platelet, while the evidence base for "de-escalation" is small.

SUMMARY & CONCLUSIONS - 71ST WORLD HEALTH ASSEMBLY Global resolution on Rheumatic Fever and Rheumatic Heart Disease adopted at the WHA Following years of campaigning and advocacy from WHF, our members and the global RHD community, we are delighted to announce that on Friday 25 May, Member States of the World Health Organization unanimously adopted a Global Resolution on Rheumatic Fever and Rheumatic Heart Disease at the World Health Assembly in Geneva, Switzerland.